Literature DB >> 15956636

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials.

Shamir R Mehta1, Christopher P Cannon, Keith A A Fox, Lars Wallentin, William E Boden, Rudolf Spacek, Petr Widimsky, Peter A McCullough, David Hunt, Eugene Braunwald, Salim Yusuf.   

Abstract

CONTEXT: Patients with unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) can be cared for with a routine invasive strategy involving coronary angiography and revascularization or more conservatively with a selective invasive strategy in which only those with recurrent or inducible ischemia are referred for acute intervention.
OBJECTIVE: To conduct a meta-analysis that compares benefits and risks of routine invasive vs selective invasive strategies. DATA SOURCES: Randomized controlled trials identified through search of MEDLINE and the Cochrane databases (1970 through June 2004) and hand searching of cross-references from original articles and reviews. STUDY SELECTION: Trials were included that involved patients with unstable angina or NSTEMI who received a routine invasive or a selective invasive strategy. DATA EXTRACTION: Major outcomes of death and myocardial infarction (MI) occurring from initial hospitalization to the end of follow-up were extracted from published results of eligible trials. DATA SYNTHESIS: A total of 7 trials (N = 9212 patients) were eligible. Overall, death or MI was reduced from 663 (14.4%) of 4604 patients in the selective invasive group to 561 (12.2%) of 4608 patients in the routine invasive group (odds ratio [OR], 0.82; 95% confidence interval [CI], 0.72-0.93; P = .001). There was a nonsignificant trend toward fewer deaths (6.0% vs 5.5%; OR, 0.92; 95% CI, 0.77-1.09; P = .33) and a significant reduction in MI alone (9.4% vs 7.3%; OR, 0.75; 95% CI, 0.65-0.88; P<.001). Higher-risk patients with elevated cardiac biomarker levels at baseline benefited more from routine intervention, with no significant benefit observed in lower-risk patients with negative baseline marker levels. During the initial hospitalization, a routine invasive strategy was associated with a significantly higher early mortality (1.1% vs 1.8% for selective vs routine, respectively; OR, 1.60; 95% CI, 1.14-2.25; P = .007) and the composite of death or MI (3.8% vs 5.2%; OR, 1.36; 95% CI, 1.12-1.66; P = .002). But after discharge, the routine invasive strategy was associated with fewer subsequent deaths (4.9% vs 3.8%; OR, 0.76; 95% CI, 0.62-0.94; P = .01) and the composite of death or MI (11.0% vs 7.4%; OR, 0.64; 95% CI, 0.56-0.75; P<.001). At the end of follow-up, there was a 33% reduction in severe angina (14.0% vs 11.2%; OR, 0.77; 95% CI, 0.68-0.87; P<.001) and a 34% reduction in rehospitalization (41.3% vs 32.5%; OR, 0.66; 95% CI, 0.60-0.72; P<.001) with a routine invasive strategy.
CONCLUSIONS: A routine invasive strategy exceeded a selective invasive strategy in reducing MI, severe angina, and rehospitalization over a mean follow-up of 17 months. But routine intervention was associated with a higher early mortality hazard and a trend toward a mortality reduction at follow-up. Future strategies should explore ways to minimize the early hazard and enhance later benefits by focusing on higher-risk patients and optimizing timing of intervention and use of proven therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956636     DOI: 10.1001/jama.293.23.2908

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  120 in total

1.  Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial.

Authors:  P A Poole-Wilson; S J Pocock; K A A Fox; R A Henderson; D J Wheatley; D A Chamberlain; T R D Shaw; T C Clayton
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

Review 2.  Routine invasive versus conservative management in non-ST-elevation acute coronary syndromes.

Authors:  Peter R Sinnaeve
Journal:  J Cardiovasc Transl Res       Date:  2011-11-01       Impact factor: 4.132

Review 3.  Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2).

Authors:  Shehzad Sami; James T Willerson
Journal:  Tex Heart Inst J       Date:  2010

4.  Clinical profile of acute myocardial infarction in elderly patients.

Authors:  Lovleen C Bhatia; Ruchi H Naik
Journal:  J Cardiovasc Dis Res       Date:  2013-06-18

5.  Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE).

Authors:  K A A Fox; F A Anderson; O H Dabbous; P G Steg; J López-Sendón; F Van de Werf; A Budaj; E P Gurfinkel; S G Goodman; D Brieger
Journal:  Heart       Date:  2006-06-06       Impact factor: 5.994

6.  Determining optimal population rates of cardiac catheterization: a phantom alternative?

Authors:  Madhu K Natarajan; Amiram Gafni; Salim Yusuf
Journal:  CMAJ       Date:  2005-07-05       Impact factor: 8.262

Review 7.  Non ST segment elevation acute coronary syndromes: A simplified risk-orientated algorithm.

Authors:  David H Fitchett; Bjug Borgundvaag; Warren Cantor; Eric Cohen; Sanjay Dhingra; Stephen Fremes; Milan Gupta; Michael Heffernan; Heather Kertland; Mansoor Husain; Anatoly Langer; Eric Letovsky; Shaun G Goodman
Journal:  Can J Cardiol       Date:  2006-06       Impact factor: 5.223

8.  Underuse of revascularisation in acute coronary syndromes.

Authors:  Franz-Josef Neumann; Heinz Joachim Büttner
Journal:  Heart       Date:  2007-02       Impact factor: 5.994

Review 9.  Optimal revascularization for complex coronary artery disease.

Authors:  Javaid Iqbal; Patrick W Serruys; David P Taggart
Journal:  Nat Rev Cardiol       Date:  2013-09-17       Impact factor: 32.419

10.  Current trends in coronary revascularization.

Authors:  Shannon M Dunlay; Charanjit S Rihal; Thoralf M Sundt; Yariv Gerber; Véronique L Roger
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.